Chinese Scholars' CAR-T Cell Therapy Research Featured on Nature Headline
TapTechNews October 6th news, the research of Chinese scholars on autologous chimeric antigen receptor (CAR)-T cell therapy was featured on theheadline of Nature (Nature) official website.
On October 5th, the headline article on the Nature official website was a report titled World-first therapy using donor cells sends autoimmune diseases into remission. It introduced a research resultfrom the Chinese team and published in the Cell (Cell) journal. This report was published on October 4th, 2024, local time.
The paper reported by Nature was published online in Cell on July 16th, 2024, Beijing time. Led by the team of Professor Xu Huji from the Second Affiliated Hospital of the Naval Military Medical University (Shanghai Changzheng Hospital), in cooperation with researchers from East China Normal University and the Second Affiliated Hospital of Zhejiang University School of Medicine, they used CRISPR-Cas9 gene editing technology to genetically engineer targeted CD19 CAR-T cells from healthy donor sources anddeveloped a new generation of allogeneic universal CAR-T therapy, helping 3 patients with rheumatic immune diseases achieve long-term remission.
Nature wrote in the article: The success of this therapy in these three people brings the hope of large-scale production of cutting-edge CAR-T therapy.
The official of Shanghai Changzheng Hospital said: The publication of this research result in Cell indicates that through years of efforts by Professor Xu Huji's team, it not only provides a new treatment option for patients with rheumatic immune diseases who currently lack effective treatment methods, but also demonstrates the great potential of universal CAR-T cell therapy in terms of effectiveness and safety,pushing the treatment of rheumatic immune diseases into a new chapter.
TapTechNews attached the original link as follows:
https://www.nature.com/articles/d41586-024-03209-4